75348780LYM1001
Research type
Research Study
Full title
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL
IRAS ID
290913
Contact name
David Wright
Contact email
Sponsor organisation
Janssen-Cilag International NV
Eudract number
2020-001183-29
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 4 months, 3 days
Research summary
B cell Non-Hodgkin lymphoma (NHL) is an uncommon cancer that develops in the lymphatic system, which is a network of vessels and glands spread throughout the body. Chronic lymphocytic leukaemia (CLL), a type of cancer affecting the white blood cells that develops slowly over time. The drug being studied is called JNJ-75348780, which is an investigational (or experimental) drug that has not been used in humans before but has only been studied in test tubes and animals. JNJ-75348780 is a liquid study drug given by injection into the body. The purpose of this research study is to find a safe dose of JNJ-75348780 that can be used for treating patients with NHL and CLL. Another purpose is to find out how long JNJ-75348780 stays in and acts on the body and how the body responds to it. There is only preliminary safety information available on the use of JNJ-75348780 in humans; therefore, administration of JNJ-75348780 may involve risks that are currently not known. Patients will be provided study drug as long as they receive benefit from the drug.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
20/WM/0306
Date of REC Opinion
7 Jan 2021
REC opinion
Further Information Favourable Opinion